First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.
Saved in:
| Title: | First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. |
|---|---|
| Authors: | Taramasso, L.1, Di Biagio, A.2 Antonio.dibiagio@hsanmartino.it, Maggiolo, F.3, Tavelli, A.4, Lo Caputo, S.5, Bonora, S.6, Zaccarelli, M.7, Caramello, P.8, Costantini, A.9, Viscoli, C.1, d'Arminio Monforte, A.10, Cozzi‐Lepri, A.11, the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group |
| Source: | HIV Medicine. Aug2018, Vol. 19 Issue 7, p475-484. 10p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
